Enzon Pharmaceuticals Sells 25% Interest in Hepatitis C Drug
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 87 (Table of Contents)
Published: 7 Sep-2007
DOI: 10.3833/pdr.v2007.i87.294 ISSN: 1756-7874
Section: Royalties
Fulltext:
Abstract
Enzon Pharmaceuticals has sold 25% of its royalty in PEG-Intron® to Drug Royalty for US$92...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.
RSS